Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
about
Towards tumor immunodiagnosticsImmune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?CIViC databaseImmunological battlefield in gastric cancer and role of immunotherapiesMonocyte and interferon based therapy for the treatment of ovarian cancer.Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer.COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.PD-L1 expression in extrahepatic cholangiocarcinoma.Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy.The immune contexture in cancer prognosis and treatment.Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes.Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancerCombined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers.PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer.Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer.Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinomaIn search of a target: PD-1 and PD-L1 profiling across glioma types.Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract CaTumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma.Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells.Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer.Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation resistant ovarian cancer patient harboring a CD274/PD-L1-genetic rearrangement.A correlative analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 expression in oropharyngeal squamous cell carcinoma.Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells.Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma.
P2860
Q26738691-1EDA387E-D814-4034-B6A3-C1AA009C34CEQ26742047-9DA83575-F66F-42E0-8BC3-D9C0AFCE9307Q27612411-5DF3599C-EE8B-4780-89CF-8F53FF5302B0Q28071836-069451F1-F704-4F02-9BA4-F4380AB4F373Q35973378-FD17D784-C59E-4494-B2F0-4B9120528319Q36261405-165BDC25-7258-411A-8FDD-CF13F525664CQ36358014-5DD3E7C2-EDFF-49E7-A96A-EC859911CF9FQ37199510-6A2BF2A2-0320-48FC-B4DA-5AF56B8AFD26Q37327597-5C6EB007-E833-4C8C-8199-776CA7E6A733Q37564425-281B2F9B-F94D-4F54-8C9E-F207CAE9D2AEQ37565108-7730EDE0-1FDE-4612-AD75-E906EE6CEE13Q37641608-FF0B78E6-7C30-432B-B9D1-678A701966BCQ37663388-9B783CA2-81D3-46BB-9312-CAA85ED3E5E4Q37716589-46A71954-5E37-43D1-94C7-7D5CE7A91D18Q38726053-CD66B2EE-82AD-4174-A7AE-CC79073B7B5CQ38728836-BF16F889-9CBC-4EC1-9992-EB448D565900Q38839112-B13829A8-809F-49B6-B3CB-042A8395D563Q39456999-3D6D4161-7BB2-4AD5-854D-13A32A83D86EQ39583147-3D256773-A8BC-481F-8B1C-DA00DD413F36Q41592956-EB2A0DB8-853F-4E3D-B018-45068D607484Q41612699-3B290852-3497-43A2-9142-39943DBF5FBFQ41695706-86C9B105-942E-4443-8A45-F85F2866F142Q41708934-F67DF2C7-1C5F-459D-B3BC-DF639EBE1BA4Q41926342-6AAE2E82-2152-411E-801B-69669DF6D4E4Q42056165-D56F050B-8BE0-4FED-93C8-9BBB8219D2D1Q42371619-1C0C7770-7D00-4FA1-A1E4-48AD9E2E2994Q42391407-816A975B-2623-47AC-8643-5C246A062E80Q42700308-086E6427-5B06-426C-A1E9-6BE2E55ECE0BQ43432645-CE7D9062-D927-4E34-AA1E-C1BCCE02F191Q46540302-087107FE-7351-451E-96AD-E1422C85FE5CQ47112946-9069421A-EEE3-46B1-A902-BEE19C1C238BQ47121377-8416E35C-A51D-420B-8EAA-8E558442129CQ47346032-67A5685D-8BC6-4C96-8FCA-6B576C4628F4Q49678489-9BA84459-BCDF-4080-8117-4DC39EDE9641Q49913387-C7E4D888-508A-48FA-95A8-5700804AC576Q50027076-5DD53BF1-CEB1-4D72-9E04-6E897322359DQ52597557-770A9CC4-160E-407B-9854-95A0895C0C7CQ52691905-1786C9CE-3DC9-498A-84DB-00465FE7EDAEQ52715784-372B3F4F-CB29-469F-97D2-1AAD7B266921Q52721812-4C3E92AF-FDA1-43B7-97D2-F701D5461836
P2860
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Prognostic impact of programme ...... an high grade serous carcinoma
@ast
Prognostic impact of programme ...... an high grade serous carcinoma
@en
Prognostic impact of programme ...... n high grade serous carcinoma.
@nl
type
label
Prognostic impact of programme ...... an high grade serous carcinoma
@ast
Prognostic impact of programme ...... an high grade serous carcinoma
@en
Prognostic impact of programme ...... n high grade serous carcinoma.
@nl
altLabel
Prognostic impact of programme ...... an high grade serous carcinoma
@en
prefLabel
Prognostic impact of programme ...... an high grade serous carcinoma
@ast
Prognostic impact of programme ...... an high grade serous carcinoma
@en
Prognostic impact of programme ...... n high grade serous carcinoma.
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Prognostic impact of programme ...... an high grade serous carcinoma
@en
P2093
Carsten Denkert
Catarina Alisa Kunze
Hagen Kulbe
Ioana Braicu
Jan Budczies
Judith Lindner
Michael Bockmayr
Stephan Wienert
P2860
P304
P3181
P356
10.18632/ONCOTARGET.6429
P407
P577
2016-01-12T00:00:00Z